SG11201404212YA - Compositions and methods of use of phorbol esters for the treatment of stroke - Google Patents

Compositions and methods of use of phorbol esters for the treatment of stroke

Info

Publication number
SG11201404212YA
SG11201404212YA SG11201404212YA SG11201404212YA SG11201404212YA SG 11201404212Y A SG11201404212Y A SG 11201404212YA SG 11201404212Y A SG11201404212Y A SG 11201404212YA SG 11201404212Y A SG11201404212Y A SG 11201404212YA SG 11201404212Y A SG11201404212Y A SG 11201404212YA
Authority
SG
Singapore
Prior art keywords
stroke
compositions
treatment
methods
phorbol esters
Prior art date
Application number
SG11201404212YA
Other languages
English (en)
Inventor
Zheng Tao Han
Hung-Fong Chen
Original Assignee
Biosuccess Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosuccess Biotech Co Ltd filed Critical Biosuccess Biotech Co Ltd
Publication of SG11201404212YA publication Critical patent/SG11201404212YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
SG11201404212YA 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters for the treatment of stroke SG11201404212YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261588165P 2012-01-18 2012-01-18
US201261588162P 2012-01-18 2012-01-18
US201261588167P 2012-01-18 2012-01-18
PCT/US2013/022325 WO2014011209A1 (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters for the treatment of stroke

Publications (1)

Publication Number Publication Date
SG11201404212YA true SG11201404212YA (en) 2014-10-30

Family

ID=48799818

Family Applications (12)

Application Number Title Priority Date Filing Date
SG10201912660UA SG10201912660UA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG11201404211PA SG11201404211PA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912674SA SG10201912674SA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG11201404212YA SG11201404212YA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters for the treatment of stroke
SG10201912629UA SG10201912629UA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201902370QA SG10201902370QA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912677PA SG10201912677PA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912676RA SG10201912676RA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912642RA SG10201912642RA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912649XA SG10201912649XA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912667QA SG10201912667QA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912653PA SG10201912653PA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG10201912660UA SG10201912660UA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG11201404211PA SG11201404211PA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912674SA SG10201912674SA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters

Family Applications After (8)

Application Number Title Priority Date Filing Date
SG10201912629UA SG10201912629UA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201902370QA SG10201902370QA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912677PA SG10201912677PA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912676RA SG10201912676RA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912642RA SG10201912642RA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912649XA SG10201912649XA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912667QA SG10201912667QA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters
SG10201912653PA SG10201912653PA (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters

Country Status (18)

Country Link
US (1) US20170096386A1 (enExample)
EP (2) EP2804601B1 (enExample)
JP (5) JP6336914B2 (enExample)
KR (4) KR102102677B1 (enExample)
CN (4) CN110025609A (enExample)
AU (7) AU2013209524A1 (enExample)
BR (2) BR112014017716A8 (enExample)
CA (3) CA2862301C (enExample)
IL (2) IL233676A0 (enExample)
MX (4) MX373291B (enExample)
MY (5) MY173042A (enExample)
NZ (4) NZ726666A (enExample)
PH (10) PH12014501656B1 (enExample)
RU (3) RU2659684C2 (enExample)
SG (12) SG10201912660UA (enExample)
TW (6) TW201350110A (enExample)
WO (2) WO2014011209A1 (enExample)
ZA (3) ZA201405564B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
ES2584327T3 (es) 2007-01-31 2016-09-27 Biosuccess Biotech Company Composiciones y métodos de uso de ésteres de forbol
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
BR112014017716A8 (pt) * 2012-01-18 2021-03-02 Biosuccess Biotech Co Ltd composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
CA2944720A1 (en) * 2014-04-16 2015-10-22 Northern Sydney Local Health District Compositions and methods for the treatment or prevention of neurodegenerative disorders
WO2016040656A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by prostratin
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
WO2016122289A2 (ko) * 2015-01-30 2016-08-04 고려대학교산학협력단 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
KR20160107426A (ko) 2015-03-04 2016-09-19 임세영 구두 굽 및 그 제조방법
KR101710674B1 (ko) * 2015-07-22 2017-02-27 가톨릭대학교 산학협력단 Epo 수용체 및 pkc 동시 표적물질을 유효성분으로 포함하는 빈혈의 예방 또는 치료용 약학 조성물 및 이의 용도
CN106420687A (zh) * 2016-10-11 2017-02-22 孙君重 防护肠辐射损伤的方法及tpa的用途
CA3084139C (en) * 2017-11-15 2023-02-28 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
KR102059160B1 (ko) * 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
CN108689851B (zh) * 2018-05-28 2020-04-17 中山大学 一类惕各烷型二萜化合物及其制备方法和应用
CA3155650A1 (en) * 2019-09-24 2021-04-01 K-Gen, Inc. Diterpenoid compounds that act on protein kinase c (pkc)
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
KR102541582B1 (ko) * 2020-10-29 2023-06-12 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
CN112715542A (zh) * 2021-01-20 2021-04-30 沈阳农业大学 巴豆烷二萜类化合物的制备方法及其在制备杀线虫的杀虫剂中的应用
CN116159126A (zh) * 2022-12-31 2023-05-26 山东大学齐鲁医院 同源二聚体介导的C/EBPαS16磷酸化通过液-液相分离调节急性髓系白血病分化

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375308A (en) 1942-08-21 1945-05-08 Ibm Method of making stencil cards
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US20070009529A1 (en) 2002-03-26 2007-01-11 New York University Agents that dissolve arterial thrombi
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
EP1959969A2 (en) * 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
ES2584327T3 (es) * 2007-01-31 2016-09-27 Biosuccess Biotech Company Composiciones y métodos de uso de ésteres de forbol
WO2009151496A2 (en) * 2008-03-26 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
US20110207718A1 (en) * 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
EP2362770A4 (en) * 2008-11-21 2012-05-30 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE
RU2426535C2 (ru) * 2009-05-15 2011-08-20 Маргарита Алексеевна Морозова Применение бета-гидроксибутирата или его фармацевтически приемлемых солей для приготовления лекарственного средства, обладающего цитопротекторной активностью, включающей нейропротекторную, кардиопротекторную, противоишемическую, антигипоксическую, антистрессорную, актопротекторную и адаптогенную активности, лекарственное средство и способ профилактики, купирования и лечения с помощью этого лекарственного средства
US8575216B2 (en) * 2009-08-04 2013-11-05 Rutgers, The State University Of New Jersey Method of treatment for acute myelogenous leukemia
KR101144327B1 (ko) * 2010-04-02 2012-05-11 한국과학기술연구원 Ｐｋｃ 작용 활성제를 유효성분으로 함유하는 압상스 간질의 예방 및 치료용 조성물
BR112014017716A8 (pt) * 2012-01-18 2021-03-02 Biosuccess Biotech Co Ltd composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol

Also Published As

Publication number Publication date
AU2016203714B2 (en) 2018-01-04
NZ726666A (en) 2019-03-29
TW202425963A (zh) 2024-07-01
MX395719B (es) 2025-03-25
RU2014133517A (ru) 2016-03-10
AU2013209524A1 (en) 2014-08-14
AU2016234887B2 (en) 2018-10-04
JP6715871B2 (ja) 2020-07-01
SG10201912642RA (en) 2020-02-27
MY173042A (en) 2019-12-20
TWI802707B (zh) 2023-05-21
IL233674B (en) 2021-03-25
KR20140117564A (ko) 2014-10-07
PH12020550752A1 (en) 2021-07-26
CN104168957A (zh) 2014-11-26
TW201350111A (zh) 2013-12-16
CN108969514A (zh) 2018-12-11
JP6835778B2 (ja) 2021-02-24
PH12020550759A1 (en) 2021-07-26
MY192285A (en) 2022-08-17
SG10201912674SA (en) 2020-03-30
CA2861459A1 (en) 2013-07-25
PH12014501661A1 (en) 2014-10-20
PH12014501656B1 (en) 2022-07-29
SG10201902370QA (en) 2019-04-29
TWI817022B (zh) 2023-10-01
WO2013110006A3 (en) 2015-02-05
MY177300A (en) 2020-09-11
AU2019210621B2 (en) 2020-01-02
PH12014501656A1 (en) 2014-10-13
MX370146B (es) 2019-12-03
AU2020200954A1 (en) 2020-02-27
BR112014017716A8 (pt) 2021-03-02
JP2018109014A (ja) 2018-07-12
TWI664964B (zh) 2019-07-11
RU2659684C2 (ru) 2018-07-03
AU2019210621A1 (en) 2019-08-22
MX2019011333A (es) 2019-12-19
AU2020200954B2 (en) 2021-11-11
TW201934118A (zh) 2019-09-01
JP2021073288A (ja) 2021-05-13
CN104507466A (zh) 2015-04-08
ZA201405564B (en) 2016-02-24
IL233674A0 (en) 2014-08-31
EP2804669A1 (en) 2014-11-26
AU2016234887A1 (en) 2016-10-20
EP2804601B1 (en) 2025-04-02
TW201804991A (zh) 2018-02-16
PH12020550764A1 (en) 2021-08-16
RU2017140059A (ru) 2019-02-12
PH12020550760A1 (en) 2021-12-13
BR112014017650B1 (pt) 2023-05-02
IL233676A0 (en) 2014-08-31
RU2017140059A3 (enExample) 2021-07-06
KR102102677B1 (ko) 2020-04-22
WO2014011209A1 (en) 2014-01-16
HK1204447A1 (en) 2015-11-20
MX2014008773A (es) 2015-04-10
MX373291B (es) 2020-05-06
TW201350110A (zh) 2013-12-16
KR20190129073A (ko) 2019-11-19
RU2018108884A (ru) 2019-02-26
ZA201505443B (en) 2020-02-26
RU2014133516A (ru) 2016-03-10
MY176593A (en) 2020-08-18
BR112014017650A8 (pt) 2017-07-11
SG10201912629UA (en) 2020-02-27
CA3077480A1 (en) 2013-07-25
AU2013287280B2 (en) 2016-06-30
MY199269A (en) 2023-10-24
MX389510B (es) 2025-03-20
KR102102640B1 (ko) 2020-06-01
SG10201912677PA (en) 2020-02-27
NZ749356A (en) 2021-02-26
TW201817421A (zh) 2018-05-16
TW202118485A (zh) 2021-05-16
WO2013110006A2 (en) 2013-07-25
EP2804601A2 (en) 2014-11-26
PH12020550762A1 (en) 2021-08-16
NZ727304A (en) 2018-08-31
JP6463969B2 (ja) 2019-02-06
AU2016203714A1 (en) 2016-06-23
PH12020550768A1 (en) 2021-08-16
CN110025609A (zh) 2019-07-19
RU2650963C2 (ru) 2018-04-18
RU2018108884A3 (enExample) 2021-07-01
SG10201912653PA (en) 2020-02-27
CA2862301A1 (en) 2014-01-16
AU2013287280A1 (en) 2014-08-14
JP2015504096A (ja) 2015-02-05
KR20140129000A (ko) 2014-11-06
JP2015513315A (ja) 2015-05-07
EP2804669A4 (en) 2015-07-22
CA2862301C (en) 2020-10-20
SG10201912676RA (en) 2020-02-27
TWI666015B (zh) 2019-07-21
CA3077480C (en) 2023-03-14
NZ628294A (en) 2017-11-24
KR20200105731A (ko) 2020-09-08
JP2018203754A (ja) 2018-12-27
NZ628296A (en) 2017-02-24
JP6336914B2 (ja) 2018-06-06
SG10201912660UA (en) 2020-02-27
ZA201508059B (en) 2016-12-21
AU2017276345A1 (en) 2018-01-18
CA2861459C (en) 2020-08-25
SG11201404211PA (en) 2014-09-26
US20170096386A1 (en) 2017-04-06
HK1204461A1 (en) 2015-11-20
MX2014008776A (es) 2015-08-20
EP2804669B1 (en) 2023-03-29
PH12020550765A1 (en) 2021-12-13
EP2804601A4 (en) 2016-07-06
PH12020550755A1 (en) 2021-07-26
SG10201912649XA (en) 2020-02-27
SG10201912667QA (en) 2020-02-27
BR112014017650A2 (pt) 2021-06-08

Similar Documents

Publication Publication Date Title
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
IL233674B (en) Preparations and methods for using phorbol esters for stroke treatment
EP2847152A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME
HUE051612T2 (hu) Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
EP2922850A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
DK3292875T3 (en) Compositions and methods for treating diseases
IL238177A0 (en) Methods and preparations for the treatment of cancer
ZA201408056B (en) Compositions and methods for the treatment of mucositis
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
IL233961B (en) The composition of a phytogenic supplement and methods of its use
ZA201408065B (en) Compositions and methods for the treatment of diabetes
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
EP2916831A4 (en) RADIOGRAPHIC CONTRAST MEDIUM COMPOSITIONS AND METHODS OF USE FOR TREATING INFLAMMATION AND CONDITIONS ASSOCIATED WITH INFLAMMATION.